NORMA GOODRICH: Open Payments
NPI 1669087722 · OKEECHOBEE, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,881 in 95 payments from 13 companies in 2025. Trend: 2023 $1,214 · 2024 $1,609 · 2025 $1,881
Food & beverage: $1,769Education: $111
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 24 | $324 |
| Alkermes, Inc. | 17 | $276 |
| Teva Pharmaceuticals USA, Inc. | 7 | $275 |
| Otsuka America Pharmaceutical, Inc. | 8 | $238 |
| Axsome Therapeutics, Inc. | 11 | $182 |
| Lundbeck LLC | 10 | $179 |
| Janssen Pharmaceuticals, Inc | 5 | $123 |
| E.R. Squibb & Sons, L.L.C. | 4 | $86 |
| Supernus Pharmaceuticals, Inc. | 3 | $82 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $67 |
Products named: REXULTI, VRAYLAR, ARISTADA, Auvelity, AUSTEDO XR, INVEGA SUSTENNA, COBENFY, Qelbree.
Industry payments across FL — which companies pay providers there.
